Aspire Eyes UK Opportunity From GSK Dropping Fluticasone
Suggests Recent Discontinuation Of Flixonase Nasal Drops Leaves Open A Gap In The Market
Aspire Pharma says that its UK launch of fluticasone propionate 400mcg 1mg/ml nasal drops “further establishes Aspire as a premier specialty generics business,” noting that the product is hitting the market in the wake of GSK pulling out, “leading to a possible short supply for patients.”
